Tivozanib hydrochloride hydrate (0.04-1 mg/kg, po for 14 days) exhibits antitumor efficacy against breast, colon, hepatic, lung, ovarian, pancreatic, and prostate cancer in athymic mice model[1].
Tivozanib hydrochloride hydrate (0.2-1 mg/kg, po for 21 days) reversibly suppresses vascular permeability and angiogenesis in Calu-6 tumor bearing rats model[1].
Tivozanib hydrochloride hydrate (5 mg/kg, po, single dose) reveals a AUCinf of 44.5 μg·h/mL, Cmax of 2823 ng/mL in athymic mice model[1].
| Animal Model: | Calu-6 tumor bearing athymic mice model[1] |
| Dosage: | 0.04-1 mg/kg/day |
| Administration: | p.o., for 14-21 days |
| Result: |
Inhibited tumor growth, angiogenesis and vascular permeability. |
